JP2019528307A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528307A5
JP2019528307A5 JP2019511664A JP2019511664A JP2019528307A5 JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5 JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5
Authority
JP
Japan
Prior art keywords
phenyl
diamine
isopropylsulfonyl
pyrimidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511664A
Other languages
English (en)
Japanese (ja)
Other versions
JP7094566B2 (ja
JP2019528307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048845 external-priority patent/WO2018044767A2/en
Publication of JP2019528307A publication Critical patent/JP2019528307A/ja
Publication of JP2019528307A5 publication Critical patent/JP2019528307A5/ja
Priority to JP2022096630A priority Critical patent/JP2022120151A/ja
Application granted granted Critical
Publication of JP7094566B2 publication Critical patent/JP7094566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511664A 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類 Active JP7094566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096630A JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096630A Division JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Publications (3)

Publication Number Publication Date
JP2019528307A JP2019528307A (ja) 2019-10-10
JP2019528307A5 true JP2019528307A5 (enExample) 2020-10-01
JP7094566B2 JP7094566B2 (ja) 2022-07-04

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511664A Active JP7094566B2 (ja) 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Country Status (11)

Country Link
US (2) US10709705B2 (enExample)
EP (2) EP3504203B1 (enExample)
JP (2) JP7094566B2 (enExample)
KR (1) KR102530871B1 (enExample)
CN (2) CN115043821B (enExample)
AU (2) AU2017319135B2 (enExample)
IL (1) IL264638B (enExample)
MX (2) MX389265B (enExample)
NZ (1) NZ751713A (enExample)
SG (2) SG11201901251SA (enExample)
WO (1) WO2018044767A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726363B (zh) * 2018-07-31 2021-05-01 大陸商蘇州亞盛藥業有限公司 Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
US20220117964A1 (en) * 2019-06-25 2022-04-21 Ascentage Pharma (Suzhu) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
WO2022222932A1 (en) * 2021-04-19 2022-10-27 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
WO2024153228A1 (zh) * 2023-01-20 2024-07-25 苏州亚盛药业有限公司 Alk抑制剂或其盐、溶剂合物的结晶形式及其制备方法和应用
AU2024238523A1 (en) * 2023-03-22 2025-10-09 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
WO2025157162A1 (zh) 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233964B2 (en) 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR20130139999A (ko) 2010-10-14 2013-12-23 어리어드 파마슈티칼스, 인코포레이티드 Egfr-유도된 암의 세포 증식을 억제하는 방법
PT2670401E (pt) 2011-02-02 2015-10-12 Novartis Ag Métodos de utilização de inibidores de alk
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2025508702A5 (enExample)
EP2488178B1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
JP2019511528A5 (enExample)
JP2015533177A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2017008088A5 (enExample)
CN103402519B (zh) 肿瘤治疗剂
JP2020007311A5 (enExample)
JP2019526615A5 (enExample)
JP2017528487A5 (enExample)
JP2018517686A5 (enExample)
JP2016538313A5 (enExample)
JP2015508103A5 (enExample)
JP2011001339A5 (enExample)
JP2016522232A5 (enExample)
JP2019501195A5 (ja) 腫瘍を処置するための抗egfr組み合わせ
JP2014513110A5 (enExample)
JP2006507271A5 (enExample)
JP2015514806A5 (enExample)
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
JP2016525076A5 (enExample)
JP2015504067A5 (enExample)
JP2016526540A5 (enExample)
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
JP2011515397A5 (enExample)